Search

Search Constraints

You searched for: Author/Creator Bossard, C.

Search Results

1. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Issue 1 (January 2018)

2. GENE EXPRESSION PROFILING USING a RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T‐CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLS‐NOS. (June 2017)

4. INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY. (June 2017)

5. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Issue 9 (September 2019)

7. REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE. (12th June 2019)

8. SM04690, A potential disease-modifying treatment for knee osteoarthritis, functions through inhibition of CLK2 and DYRK1A, novel molecular regulators of Wnt signaling, chondrogenesis, and inflammation. (April 2019)

9. VALIDATION OF REAL‐TIME MULTIPLEX LIGATION PROBE AMPLIFICATION (RT‐MLPA) TO ANALYZE LYMPHOMA TRANSCRIPTOME FROM FORMALIN‐FIXED PARAFFIN EMBEDDED SAMPLES. (12th June 2019)